

Product information



Information about other products is available at: www.IBL-America.com

ImmunoGuide®

Instructions for Use

Aflibercept ELISA

Enzyme immunoassay for the determination
of free Aflibercept in serum and plasma

REF: TM09028



12X8



2-8°C

For Research Use Only - Not for Use in Diagnostic Procedures

Manufactured for
Immuno-Biological Laboratories Inc. (IBL-America)
8201 Central Avenue, NE, Suite P
Minneapolis, MN 55432
Tel: 763-780-2955 Toll Free: 1-888-523-1246
www.IBL-America.com

| <u>Contents</u> | <u>Page</u> |
|--|--------------------|
| 1. Intended Use | 2 |
| 2. Summary and Explanation | 2 |
| 3. Principle of the Test | 2 |
| 4. Warnings and Precautions | 2 |
| 5. Storage and Stability of the Kit | 3 |
| 6. Specimen Collection, Handling and Storage | 3 |
| 7. Contents of the Kit | 4 |
| 8. Materials Required but not Supplied | 4 |
| 9. Procedure Notes | 4 |
| 10. Pre-Test Setup Instructions | 5 |
| 10.1. Preparation of Components | 5 |
| 10.2. Dilution of Standards and Samples | 6 |
| 11. Test Procedure | 6 |
| 11.1. General Remarks | 6 |
| 11.2. Assay Procedure | 7 |
| 11.3. Quality Control | 8 |
| 11.4. Calculation of Results | 8 |
| 12. Assay characteristics | 9 |
| 12.1. Specificity | 9 |
| 12.2. Sensitivity | 9 |
| 12.3. Precision | 10 |
| 12.4. Recovery | 10 |
| 13. Automation | 10 |
| 14. References | 10 |

1. INTENDED USE

Enzyme immunoassay for the determination of free Aflibercept in serum and plasma.

2. SUMMARY AND EXPLANATION

The drug Aflibercept (trade names Eylea[®], Zaltrap[®]) is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human IgG1. Aflibercept has broad affinity for all ligands that bind to these receptors, including isoforms of VEGF-A, VEGF-B, and placental growth factors. Aflibercept demonstrated antitumour effects and antiangiogenic activity as a single agent and enhanced activity in combination with chemotherapy.

Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Aflibercept in order to potentially avoid some side effects with a reliable method might be beneficial.

3. PRINCIPLE OF THE TEST

This ELISA assay is based on sandwich type ELISA. Diluted standards and samples (serum or plasma) are incubated in the microtiter plate coated with recombinant human vascular endothelial growth factor-A (rhVEGF-A). After incubation, the wells are washed. A horseradish peroxidase (HRP) conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Aflibercept pre-captured by the rhVEGF-A on the surface of the wells. Following incubation, the wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. The color developed is proportional to the amount of Aflibercept in the sample or standard. Results of samples can be determined by using the standard curve.

4. WARNINGS AND PRECAUTIONS

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.

2. In case of severe damage of the kit package, please contact *IBL-America* or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.

3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.

4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.

5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.

6. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.
7. Avoid contact with Stop solution. It may cause skin irritations and burns.
8. If any component of this kit contains human serum or plasma it is indicated and if so, it has been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.
9. Some reagents contain sodium azide (NaN_3) as preservatives. In case of contact with eyes or skin, flush immediately with water. NaN_3 may react with lead and copper plumbing to form explosive metal azides. When disposing reagents, flush with large volume of water to avoid azide build-up

5. STORAGE AND STABILITY OF THE KIT

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2–8°C.

6. SPECIMEN COLLECTION, HANDLING AND STORAGE

Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

| | | | |
|------------|-------|-------------------|--|
| Storage: | 2-8°C | ≤-20°C (Aliquots) | Keep away from heat or direct sun light Avoid repeated freeze-thaw cycles |
| Stability: | 3 d | 6 mon | |

7. CONTENTS OF THE KIT

| QUANTITY | COMPONENT |
|------------|---|
| 1 x 12 x 8 | Microtiter ELISA Plate Break apart strips coated with recombinant human vascular endothelial growth factor-A (rhVEGF-A). |
| 5 x 0.5 mL | Aflibercept Standards A-E, Concentrate (10X) 2000; 600; 200; 60; and 0 ng/mL Used for construction of the standard curve. Contains Aflibercept, proteins, stabilizer and <15 mM NaN ₃ . |
| 1 x 12 mL | Assay Buffer Blue colored. Ready to use. Contains proteins and <15 mM NaN ₃ . |
| 1 x 60 mL | Dilution Buffer, Concentrate (5X) Contains orange dye, proteins and <15 mM NaN ₃ . |
| 1 x 12 mL | Enzyme Conjugate Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated anti-human IgG mouse monoclonal antibody, Proclin [®] and stabilizers. |
| 1 x 12 mL | TMB Substrate Solution Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB). |
| 1 x 12 mL | Stop Solution Ready to use. 1 N Hydrochloric acid (HCl). |
| 1 x 50 mL | Wash Buffer, Concentrate (20x) Contains buffer, Tween [®] 20 and Kathon [™] . |
| 2 x 1 | Adhesive Seal For sealing microtiter plate during incubation. |

8. MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (< 3% CV) and tips to deliver 5-1000 µL.
2. Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
3. Wash bottle, automated or semi-automated microtiter plate washing system.
4. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pre-treatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared readily at the appropriate time. Allow all reagents and specimens to reach room temperature (20-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant.

10. PRE-TEST SETUP INSTRUCTIONS

10.1. Preparation of Components*

| Dilute/dissolve | Component | | Diluent | Relation | Remarks | Storage | Stability |
|-----------------|-----------------|--------------|-----------------|----------|---|---------|-----------|
| 10 mL | Wash Buffer | up to 200 mL | Distilled Water | 1:20 | Warm up at 37°C to dissolve crystals. Mix vigorously. | 2-8 °C | 4 w |
| 10 mL | Dilution Buffer | up to 50 mL | Distilled Water | 1:5 | | 2-8 °C | 4 w |


* Prepare Wash and Dilution Buffers before starting the assay procedure.

10.2. Dilution of Standards and Samples

The dilutions depicted below are examples of how to obtain final dilutions for standards and samples. Standards and samples should be properly diluted as homogenous mixture before starting the assay procedure. It is recommended mixing the standards and samples well to homogenous solution at each dilution step. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

1. 10 μL of standard added to 90 μL of 1X dilution buffer, giving the total volume of 100 μL and a dilution of 1:10.
2. 10 μL of sample added to 990 μL of 1X dilution buffer, giving the total volume of 1000 μL and a dilution of 1:100.
3. Samples with a drug concentration above the measuring range should be rated as ">highest standard". The result should not be extrapolated. The sample in question should be further diluted with 1X Dilution Buffer and then retested.

Standard/Sample Dilution



11. TEST PROCEDURE

11.1. GENERAL REMARKS

- 11.1.1. Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.
- 11.1.2. All Standards should be run with each series of unknown samples.
- 11.1.3. Standards should be subject to the same manipulations and incubation times as the samples being tested.
- 11.1.4. All steps of the test should be completed without interruption.
- 11.1.5. Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

11.1.6. The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette. Such neutral plates are available from the kit manufacturer upon request.

11.2. ASSAY PROCEDURE

| | |
|-----|---|
| 1. | Pipette 100 μl of Assay Buffer into each of the wells to be used. |
| 2. | <p>Pipette 75 μl of each 1:10 Diluted Standard, and 1:100 Diluted Samples into the respective wells of the microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided.</p> <p><u>Wells</u></p> <p>A1: Standard A B1: Standard B C1: Standard C D1: Standard D E1: Standard E F1 and so on: Samples (Serum/Plasma)</p> |
| 3. | Cover the plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 60 min at room temperature (RT, 20-25°C). |
| 4. | Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 3 X 300 μl of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel. |
| 5. | Pipette 100 μl of Enzyme Conjugate (HRP-anti human IgG mAb) into each well. |
| 6. | Cover plate with adhesive seal. Shake plate carefully by tapping several times. Incubate the plate on a bench top for 30 min at RT. |
| 7. | Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate 3 X 300 μl of Diluted Wash Buffer per well. Remove excess solution by tapping the inverted plate on a paper towel. |
| 8. | Pipette 100 μl of Ready-to-Use TMB Substrate Solution into each well. |
| 9. | Incubate 15 min at RT. Avoid exposure to direct sunlight. |
| 10. | Stop the substrate reaction by adding 100 μl of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow. |
| 11. | Measure optical density (OD) with a photometer at 450 nm (Reference at OD620 nm is optional) within 15 min after pipetting the Stop Solution. |

11. 3. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover, the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

11. 4. CALCULATION OF RESULTS


A standard curve should be calculated using the standard concentration (X-axis) versus the OD450 (or OD450/620) values (Y-axis). This can be done manually using graph paper or with a computer program. Concerning the data regression by computer, it is recommended to primarily use the "4 Parameter Logistic (4PL)" or alternatively the "point-to-point calculation". In case of manual plot there are 2 options: Semilog graph (see Fig. A) or linear graph (see Fig. B). Semilog graph paper is available at <http://www.papersnake.com/logarithmic/semilogarithmic/>.

The concentration of the samples can be read from this standard curve as follows. Using the absorbance value for each sample, determine the corresponding concentration of the drug from the standard curve. This value always has to be multiplied by the individual dilution factor (usually 100). If any diluted sample is reading greater than the highest standard, it should be further diluted (in such a case, a 1:500 final dilution of the sample is proposed) appropriately with 1X Dilution Buffer and retested. Also, this second dilution has to be used for calculation of the final result. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

Typical Calibration Curve

(All steps were performed at 23°C. Just an example. Do not use it for calculation!)

| 1:10 Diluted Standard | A | B | C | D | E |
|-----------------------|-------|-------|-------|-------|-------|
| Concentration (ng/mL) | 200 | 60 | 20 | 6 | 0 |
| Mean OD450/620 nm | 2.989 | 1.155 | 0.387 | 0.103 | 0.048 |



12. ASSAY CHARACTERISTICS

12.1. SPECIFICITY

There is no cross reaction with any other proteins present in native human serum. A screening test was performed with 48 different native human sera. All produced OD_{450/620 nm} values less than the mean OD of standard D. No cross reaction was observed with the other therapeutic antibodies tested (Tocilizumab, Cetuximab, Etanercept, Infliximab, Rituximab and Trastuzumab) at concentrations up to 2 mg/mL. However, Bevacizumab resulted in full cross-reaction as expected. Ranibizumab, another anti-VEGF therapeutic antibody consisted of Fab fragment only, produced a mean OD less than the mean OD of standard D.

12.2. SENSITIVITY

The lowest detectable level that can be clearly distinguished from the zero standard is 5 ng/mL (zero standard +2SD read from the curve) under the above-described conditions.

12.3. PRECISION

Intra-assay CV: <10%.

Inter-assay CV: <10%.

12.4. RECOVERY

Recovery rate was found to be >95% with native serum and plasma samples when spiked with exogenous Aflibercept.

13. AUTOMATION

The *ImmunoGuide* Aflibercept ELISA is suitable also for being used by an automated ELISA processor.

14. REFERENCES

1. Park SJ, Choi Y, Na YM, Hong HK, Park JY, Park KH, Chung JY, Woo SJ. Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model. *Invest Ophthalmol Vis Sci.* 2016;57(6):2612-7.
2. Stewart MW1, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). *Retina.* 2012;32(3):434-57.
3. Arnott C, Punnia-Moorthy G, Tan J, Sadeghipour S, Bursill C, Patel S. The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells. *PLoS One.* 2016;11(3):e0150688. doi: 10.1371.
4. Takahashi H, Nomura Y, Nishida J, Fujino Y, Yanagi Y, Kawashima H. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs. *Invest Ophthalmol Vis Sci.* 2016;57(2):462-6.
5. Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M. Response to anti-VEGF-A treatment of endothelial cells in vitro. *Exp Eye Res.* 2016;146:128-36.
6. Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes. *Invest Ophthalmol Vis Sci.* 2015;56(11):6501-5.
7. Celik N, Scheuerle A, Auffarth GU, Kopitz J, Dithmar S. Intraocular Pharmacokinetics of Aflibercept and Vascular Endothelial Growth Factor-A. *Invest Ophthalmol Vis Sci.* 2015;56(9):5574-8.
8. Giurdanella G, Anfuso CD, Olivieri M, Lupo G, Caporarello N, Eandi CM, Drago F, Bucolo C, Salomone S. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway. *Biochem Pharmacol.* 2015;96(3):278-87.
9. Zehetner C, Bechrakis NE, Stattin M, Kirchmair R, Ulmer H, Kralinger MT, Kieselbach GF. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy. *Invest Ophthalmol Vis Sci.* 2015;56(5):3279-86.

10. Klettner A, Grotelüschen S, Treumer F, Roeder J, Hillenkamp J. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage. *Br J Ophthalmol*. 2015;99(6):864-9.
11. Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME. Ziv-aflibercept in macular disease. *Br J Ophthalmol*. 2015;99(8):1055-9.
12. Park SJ, Oh J, Kim YK, Park JH, Park JY, Hong HK, Park KH, Lee JE, Kim HM, Chung JY, Woo SJ. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model. *Eye (Lond)*. 2015;29(4):561-8.
13. Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. *Acta Ophthalmol*. 2015;93(2):e154-9. doi: 10.1111/aos.12604.
14. Klettner A, Recber M, Roeder J. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture. *Graefes Arch Clin Exp Ophthalmol*. 2014;252(10):1593-8.
15. Yoshida I, Shiba T, Taniguchi H, Takahashi M, Murano T, Hiruta N, Hori Y, Bujo H, Maeno T. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol*. 2014;252(9):1483-9.
16. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Le K, Maia M, Visich JE. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. *Br J Ophthalmol*. 2014;98(12):1636-41.
17. Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. *Am J Ophthalmol*. 2014;158(4):738-744.
18. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. *Target Oncol*. 2013;8(2):117-25.
19. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. *Clin Cancer Res*. 2011;17(14):4872-81.
20. Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WM. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. *Cancer Biol Ther*. 2010;10(12):1326-33.